Somatostatin receptor biology in neuroendocrine and pituitary tumours: Part 1 - molecular pathways

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 11, 2010, Pages 2570-2584

  Cakir, Mehtap ^a   Dworakowska, Dorota ^b,c   Grossman, Ashley ^c  

^a SELCUK UNIVERSITY   (Turkey)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Molecular biology; Receptor signalling; Somatostatin; Somatostatin receptor

Indexed keywords

SOMATOSTATIN RECEPTOR;

ARTICLE; HUMAN; HYPOPHYSIS TUMOR; METABOLISM; NEUROENDOCRINE TUMOR; SIGNAL TRANSDUCTION;

HUMANS; NEUROENDOCRINE TUMORS; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION;

EID: 78649719156     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01125.x     Document Type: Article

References (172)

1. Bronstein MD. Acromegaly: molecular expression of somatostatin receptor subtypes and treatment outcome. In: Arzt E, Bronstein M, Guitelman M, editors. Front horm res, pituitary today: molecular, physiological and clinical aspects. Basel Karger; 2006. pp. 129-34.
2. Sam S, Frohman LA. Normal physiology of hypothalamic pituitary regulation. Endocrinol Metab Clin N Am. 2008; 37: 1-22.
3. Reichlin S. Somatostatin. N Engl J Med. 1983; 309: 1495-501.
4. Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs. 2009; 18: 1297-316.
5. Shen LP, Pictet RL, Rutter WJ. Human somatostatin I: sequence of the cDNA. Proc Natl Acad Sci USA. 1982; 79: 4575-79.
6. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20: 157-98.
7. Moller LN, Stidsen CE, Hartmann B, et al Somatostatin receptors. Biochim Biophys Acta. 2003; 1616: 1-84.
8. Low MJ. Neuroendocrinology. In: Melmed S, editor. Williams textbook of endocrinology. Philadelphia Saunders Elsevier; 2008. pp. 85-155.
9. Ferone D, Gatto F, Arvigo M, et al The clinical-molecular interface of somatostatin, dopamine and their receptors in pituitary pathophysiology. J Mol Endocrinol. 2009; 42: 361-70.
10. Pyronnet S, Bousquet C, Najib S, et al Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008; 286: 230-7.
11. Gahete MD, Durán-Prado M, Luque RM, et al Are somatostatin and cortistatin two siblings in regulating endocrine secretions?In vitro work ahead. Mol Cell Endocrinol. 2008; 286: 128-34.
12. Siehler S, Nunn C, Hannon J, et al Pharmacological profile of somatostatin and cortistatin receptors. Mol Cell Endocrinol. 2008; 286: 26-34.
13. Yang SK, Chen C. Involvement of somatostatin receptor subtypes in membrane ion channel modification by somatostatin in pituitary somatotropes. Clin Exp Pharmacol Physiol. 2007; 34: 1221-7.
14. Craft S, Asthana S, Newcomer JW, et al Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry. 1999; 56: 1135-40.
15. Gastambide F, Lepousez G, Viollet C, et al Cooperation between hippocampal somatostatin receptor subtypes 4 and 2: functional relevance in interactive memory systems. Hippocampus. 2009; doi:
16. Cheung NW, Boyages SC. Somatostatin-14 and its analog octreotide exert a cytostatic effect on GH3 rat pituitary tumor cell proliferation via a transient G0/G1 cell cycle block. Endocrinology. 1995; 136: 4174-81.
17. Lopez F, Estève JP, Buscail L, et al Molecular mechanisms of antiproliferative effect of somatostatin: involvement of a tyrosine phosphatase. Metabolism. 1996; 45: 14-16.
18. Hoyer D, Bell GI, Berelowitz M, et al Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995; 16: 86-88.
19. Weckbecker G, Lewis I, Albert R, et al Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov. 2003; 2: 999-1017.
20. Bousquet C, Guillermet J, Vernejoul F, et al Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis. 2004; 36: S2-7.
21. Liu Q, Cescato R, Dewi DA, et al Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol Pharmacol. 2005; 68: 90-101.
22. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging. 2003; 30: 781-793.
23. Missale C, Nash SR, Robinson SW, et al Dopamine receptors: from structure to function. Physiol Rev. 1998 78 189-225.
24. Hofland LJ, Lamberts SWJ. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003; 24: 28-47.
25. Jacobs S, Schulz S. Intracellular trafficking of somatostatin receptors. Mol Cell Endocrinol. 2008; 286: 58-62.
26. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev. 1995; 16: 427-42.
27. Eglen RM. Emerging concepts in GPCR function-the influence of cell phenotype on GPCR pharmacology. Proc West Pharmacol Soc. 2005; 48: 31-4.
28. Cervia D, Bagnoli P. An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther. 2007; 116: 322-41.
29. Rocheville M, Lange DC, Kumar U, et al Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000; 288: 154-7.
30. Rocheville M, Lange DC, Kumar U, et al Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000; 275: 7862-9.
31. Pfeiffer M, Koch T, Schröder H, et al Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem. 2002; 277: 19762-72.
32. Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal. 2009; 21: 428-39.
33. Durán-Prado M, Malagón MM, Gracia-Navarro F, et al Dimerization of G protein-coupled receptors: new avenues for somatostatin receptor signalling, control and functioning. Mol Cell Endocrinol. 2008; 286: 63-8.
34. Cervia D, Nunn C, Fehlmann D, et al Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br J Pharmacol. 2003; 139: 109-21.
35. 2+ and luciferase expression in CHO-K1 cells. Br J Pharmacol. 2004; 142: 150-60.
36. Cescato R, Loesch KA, Waser B, et al Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways. Mol Endocrinol. 2010; 24: 240-9.
37. Tulipano G, Schulz S. Novel insights in somatostatin receptor physiology. Eur J Endocrinol. 2007; 156: S3-11.
38. Lahlou H, Guillermet J, Hortala M, et al Molecular signaling of somatostatin receptors. Ann NY Acad Sci. 2004; 1014: 121-31.
39. Waser B, Tamma ML, Cescato R, et al Highly efficient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J Nucl Med. 2009; 50: 936-41.
40. Koch CA, Pacak K, Chrousos GP. Endocrine tumors. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. Philadelphia Lippincott Williams & Wilkins; 2006. pp. 1139-72.
41. Gonzalez-Maeso J, Sealfon SC. Hormone signalling via G protein-coupled receptors. In: DeGroot LJ, Jameson JL, editors. Endocrinology. Philadelphia Elsevier Saunders; 2006. pp. 177-203.
42. Schonbrunn A. Somatostatin action in pituitary cells involves two independent transduction mechanism. Metabolism. 1990; 39: 96-100.
43. Meyerhof W. The elucidation of somatostatin receptor functions: a current view. Rev Physiol Biochem Pharmacol. 1998; 133: 55-108.
44. Kleuss C, Scherubl H, Hescheler J, et al Selectivity in signal transduction determined by gamma subunits of heterotrimeric G proteins. Science. 1993; 259: 832-34.
45. Kleuss C, Hescheler J, Ewel C, et al Assignment of G-protein subtypes to specific receptors inducing inhibition of calcium currents. Nature. 1991; 353: 43-8.
46. Komatsuzaki K, Murayama Y, Giambarella U, et al A novel system that reports the G-proteins linked to a given receptor: a study of type 3 somatostatin receptor. FEBS Lett. 1997; 406: 165-70.
47. Havt A, Schally AV, Halmos G, et al The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA. 2005; 102: 17424-9.
48. Rekasi Z, Czompoly T, Schally AV, et al Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA. 2000; 97: 10561-6.
49. Reisine T, Kong H, Raynor K, et al Splice variant of the somatostatin receptor 2 subtype, somatostatin receptor 2B, couples to adenylyl cyclase. Mol Pharmacol. 1993; 44: 1016-20.
50. Vanetti M, Kouba M, Wang X, et al Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett. 1992; 311: 290-4.
51. Durán-Prado M, Gahete MD, Martìnez-Fuentes AJ, et al Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009; 94: 2634-43.
52. Bockaert J, Fagni L, Dumuis A, et al GPCR interacting proteins (GIP). Pharmacol Ther. 2004; 103: 203-21.
53. Jean-Baptiste G, Yang Z, Greenwood MT. Regulatory mechanisms involved in modulating RGS function. Cell Mol Life Sci. 2006; 63: 1969-85.
54. Zitzer H, Honck HH, Bachner D, et al Somatostatin receptor interacting protein defines a novel family of multidomain proteins present in human and rodent brain. J Biol Chem. 1999; 274: 32997-3001.
55. Kong JL, Panetta R, Song W, et al Inhibition of somatostatin receptor 5-signaling by mammalian regulators of G-protein signaling (RGS) in yeast. Biochim Biophys Acta. 2002; 1542: 95-105.
56. Elberg G, Hipkin RW, Schonbrunn A. Homologous and heterologous regulation of somatostatin receptor 2. Mol Endocrinol. 2002; 16: 2502-14.
57. Liu Q, Schonbrunn A. Agonist-induced phosphorylation of somatostatin receptor subtype 1 (sst1). Relationship to desensitization and internalization. J Biol Chem. 2001; 276: 3709-17.
58. Roth A, Kreienkamp HJ, Meyerhof W, et al Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J Biol Chem. 1997; 272: 23769-74.
59. Moore CA, Milano SK, Benovic JL. Regulation of receptor trafficking by GRKs and arrestins. Ann Rev Physiol. 2007; 69: 451-82.
60. Reiter E, Lefkowitz RJ. GRKs and beta-arrestins: roles in receptor silencing, trafficking and signaling. Trends Endocrinol Metab. 2006; 17: 159-65.
61. Ribas C, Penela P, Murga C, et al The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta. 2006; 1768: 913-22.
62. Brasselet S, Guillen S, Vincent JP, et al Beta-Arrestin is involved in the desensitization but not in the internalization of the somatostatin receptor 2A expressed in CHO cells. FEBS Lett. 2002; 516: 124-8.
63. Kreuzer OJ, Krisch B, Dery O, et al Agonist mediated endocytosis of rat somatostatin receptor subtype 3 involves beta-arrestin and clathrin coated vesicles. J Neuroendocrinol. 2001; 13: 279-87.
64. Tulipano G, Stumm R, Pfeiffer M, et al Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J Biol Chem. 2004; 279: 21374-82.
65. Schonbrunn A. Selective agonism in somatostatin receptor signaling and regulation. Mol Cell Endocrinol. 2008; 286: 35-9.
66. Menard L, Ferguson SS, Zhang J, et al Synergistic regulation of beta2-adrenergic receptor sequestration: intracellular complement of beta-adrenergic receptor kinase and beta-arrestin determine kinetics of internalization. Mol Pharmacol. 1997; 51: 800-8.
67. Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides. 2001; 35: 1-23.
68. Olias G, Viollet C, Kusserow H, et al Regulation and function of somatostatin receptors. J Neurochem. 2004; 89: 1057-91.
69. Cescato R, Schulz S, Waser B, et al Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J Nucl Med. 2006; 47: 502-11.
70. Csaba Z, Simon A, Helboe L, et al Neurochemical characterization of receptor-expressing cell populations by in vivo agonist-induced internalization: insights from the somatostatin sst2A receptor. J Comp Neurol. 2002; 454; 192-9.
71. Dewire SM, Ahn S, Lefkowitz RJ, et al Beta-Arrestins and cell signaling. Ann Rev Physiol. 2007; 69: 483-510.
72. Engstrom M, Savola JM, Wurster S. Differential efficacies of somatostatin receptor agonists for G-protein activation and desensitization of somatostatin receptor subtype 4-mediated responses. J Pharmacol Exp Ther. 2006; 316: 1262-68.
73. Hipkin RW, Friedman J, Clark RB, et al Agonist-induced desensitization, internalization, and phosphorylation of the sst2a somatostatin receptor. J Biolog Chem. 1997; 272: 13869-76.
74. Kenakin T. Principles: receptor theory in pharmacology. Trends Pharmacol Sci. 2004; 25: 186-92.
75. Perez DM, Karnik SS. Multiple signaling states of G-protein-coupled receptors. Pharmacol Rev. 2005; 57: 147-61.
76. Pfeiffer M, Koch T, Schroder H, et al Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem. 2001; 276: 14027-36.
77. Patel RC, Kumar U, Lamb DC, et al Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA. 2002; 99: 3294-9.
78. Duran-Prado M, Bucharles C, Gonzalez BJ, et al Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Endocrinology. 2007; 148: 411-21.
79. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008; 13: 822-40.
80. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol. 2004; 66: 1-7.
81. Pfleger KD, Eidne KA. Monitoring the formation of dynamic G protein- coupled receptor-protein complexes in living cells. Biochem J. 2005; 385: 625-37.
82. Grant M, Collier B, Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem. 2004; 279: 36179-83.
83. Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem. 2004; 279: 38636-43.
84. Somvanshi RK, Billova S, Kharmate G, et al C-tail mediated modulation of somatostatin receptor type-4 homo- and heterodimerizations and signaling. Cell Signal. 2009; 21: 1396-414.
85. Grant M, Alturaihi H, Jaquet P, et al Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol. 2008; 22: 2278-92.
86. Sharif N, Gendron L, Wowchuk J, et al Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology. 2007; 148: 2095-105.
87. Baragli A, Alturaihi H, Watt HL, et al Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007; 19: 2304-16.
88. Reubi JC, Laissue JA. Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci. 1995; 16: 110-5.
89. Sharma K, Srikant CB. Induction of wild-type p53, Bax, and acidic endonuclease during somatostatin-signaled apoptosis in MCF-7 human breast cancer cells. Int J Cancer. 1998; 76: 259-66.
90. Srikant CB. Cell cycle dependent induction of apoptosis by somatostatin analog SMS 201-995 in AtT-20 mouse pituitary cells. Biochem Biophys Res Commun. 1995; 209: 400-6.
91. Lahlou H, Fanjul M, Pradayrol L, et al Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol Cell Biol. 2005; 25: 4034-45.
92. Msaouel P, Pissimissis N, Halapas A, et al Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab. 2008; 22: 341-55.
93. Koutsilieris M. Skeletal metastases in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol. 1995; 18: 51-64.
94. Gastpar H, Zoltobrocki M, Weissgerber PW. The inhibition of cancer cell stickiness by somatostatin. Res Exp Med. (Berl) 1983; 182: 1-6.
95. Laklai H, Laval S, Dumartin L, et al Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proc Natl Acad Sci USA. 2009; 106: 17769-74.
96. Ferjoux G, Bousquet C, Cordelier P, et al Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol. 2000; 94: 205-10.
97. Alderton F, Humphrey PP, Sellers LA. High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors. Mol Pharmacol. 2001; 59: 1119-28.
98. Florio T. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol Cell Endocrinol. 2008; 286: 40-8.
99. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006; 7: 833-46.
100. Pan MG, Florio T, Stork PJ. G protein activation of a hormone-stimulated phosphatase in human tumor cells. Science. 1992; 256: 1215-7.
101. Theodoropoulou M, Zhang J, Laupheimer S, et al Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res. 2006; 66: 1576-82.
102. Florio T, Yao H, Carey KD, et al Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol. 1999; 13: 24-37.
103. Lahlou H, Saint-Laurent N, Esteve JP, et al sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem. 2003; 278: 39356-71.
104. Held-Feindt J, Forstreuter F, Pufe T, et al Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells. Brain Res Mol Brain Res. 2001; 87: 12-21.
105. Cattaneo MG, Scita G, Vicentini LM. Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells. FEBS Lett. 1999; 459: 64-8.
106. Bousquet C, Delesque N, Lopez F, et al sst2 somatostatin receptor mediates negative regulation of insulin receptor signaling through the tyrosine phosphatase SHP-1. J Biol Chem. 1998; 273: 7099-106.
107. Florio T, Arena S, Thellung S, et al The activation of the phosphotyrosine phosphatase eta (r-PTP eta) is responsible for the somatostatin inhibition of PCCl3 thyroid cell proliferation. Mol Endocrinol. 2001; 15: 1838-52.
108. Kovalenko M, Denner K, Sandström J, et al Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1. J Biol Chem. 2000; 275: 16219-26.
109. Grazia Lampugnani M, Zanetti A, Corada M, et al Contact inhibition of VEGF-induced proliferation requires vascular endothelial cadherin, beta-catenin, and the phosphatase DEP-1/CD148. J Cell Biol. 2003; 161: 793-804.
110. Milarski KL, Zhu G, Pearl CG, et al Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B. J Biol Chem. 1993; 268: 23634-9.
111. Florio T, Thellung S, Corsaro A, et al Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol. 2003; 59: 115-28.
112. Dasgupta P, Singh AT, Mukherjee R. Antiproliferative and GH inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Biochem Biophys Res Commun. 1999; 259: 379-84.
113. Thangaraju M, Sharma K, Liu D, et al Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res. 1999; 59: 1649-54.
114. Zapata PD, Ropero RM, Valencia AM, et al Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1. J Clin Endocrinol Metab. 2002; 87: 915-26.
115. Zatelli MC, Piccin D, Tagliati F, et al SRC homology-2-containing protein tyrosine phosphatase-1 restrains cell proliferation in human medullary thyroid carcinoma. Endocrinology. 2005; 146: 2692-8.
116. Lopez F, Estève JP, Buscail L, et al The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J Biol Chem. 1997; 272: 24448-54.
117. Ferjoux G, Lopez F, Esteve JP, et al Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell. 2003; 14: 3911-28.
118. Pagès P, Benali N, Saint-Laurent N, et al sst2 somatostatin receptor mediates cell cycle arrest and induction of p27(Kip1). Evidence for the role of SHP-1. J Biol Chem. 1999; 274: 15186-93.
119. Guillermet J, Saint-Laurent N, Rochaix P, et al Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sci USA. 2003; 100: 155-60.
120. Teijeiro R, Rios R, Costoya JA, et al Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem. 2002; 12: 31-8.
121. Ferrante E, Pellegrini C, Bondioni S, et al Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer. 2006; 13: 955-62.
122. Guillermet-Guibert J, Saint-Laurent N, Davenne L, et al Novel synergistic mechanism for sst2 somatostatin and TNFalpha receptors to induce apoptosis: crosstalk between NF-kappaB and JNK pathways. Cell Death Differ. 2007; 14: 197-208.
123. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol. 1996; 10: 1688-96.
124. Theodoropoulou M, Tichomirowa MA, Sievers C, et al Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer. 2009; 125: 2122-6.
125. Florio T, Thellung S, Arena S, et al Somatostatin receptor 1 (SSTR1)-mediated inhibition of cell proliferation correlates with the activation of the MAP kinase cascade: role of the phosphotyrosine phosphatase SHP-2. J Physiol. 2000; 94: 239-50.
126. Reardon DB, Dent P, Wood SL, et al Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol. 1997; 11: 1062-9.
127. Murphy LO, Smith S, Chen RH, et al Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol. 2002; 4: 556-64.
128. Dent P, Wang Y, Gu YZ, et al S49 cells endogenously Express subtype 2 somatostatin receptors which couple to increase protein tyrosine phosphatase activity in membranes and down-regulate Raf-1 activity in situ. Cell Signal. 1997; 9: 539-49.
129. Reardon DB, Wood SL, Brautigan DL, et al Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatin. Biochem J. 1999; 314: 401-4.
130. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006; 6: 307-20.
131. Micke P, Hackbusch D, Mercan S, et al Regulation of tyrosine phosphatases in the adventitia during vascular remodelling. Biochem Biophys Res Commun. 2009; 382: 678-84.
132. Kappert K, Paulsson J, Sparwel J, et al Dynamic changes in the expression of DEP-1 and other PDGF receptor-antagonizing PTPs during onset and termination of neointima formation. FASEB J. 2007; 21: 523-34.
133. Albini A, Florio T, Giunciuglio D, et al Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J. 1999; 13: 647-55.
134. Badway AC, West FM, Tente SM, et al Somatostatin regulates intracellular signaling in human carotid endothelial cells. Biochem Biophys Res Commun. 2004; 319: 1222-7.
135. Barbieri F, Pattarozzi A, Gatti M, et al Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology. 2008; 149: 4736-46.
136. Arena S, Pattarozzi A, Massa A, et al An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Mol Endocrinol. 2007; 21: 229-46.
137. Bertherat J, Chanson P, Dewailly D, et al Somatostatin receptors, adenylate cyclase activity, and growth hormone (GH) response to octreotide in GH-secreting adenomas. J Clin Endocrinol Metab. 1993; 77: 1577-83.
138. Cattaneo MG, Taylor JE, Culler MD, et al Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett. 2000; 481: 271-6.
139. Ludvigse E, Stridsberg M, Taylor JE, et al Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells. Med Oncol. 2004; 21: 285-96.
140. Djordjijevic D, Zhang J, Priam M, et al Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Endocrinology. 1998; 139: 2272-7.
141. Law SF, Yasuda K, Bell GI, et al Gi alpha 3 and G(o) alpha selectively associate with the cloned somatostatin receptor subtype SSTR2. J Biol Chem. 1993; 268: 10721-7.
142. Law SF, Zaina S, Sweet R, et al Gi alpha 1 selectively couples somatostatin receptor subtype 3 to adenylyl cyclase: identification of the functional domains of this alpha subunit necessary for mediating the inhibition by somatostatin of cAMP formation. Mol Pharmacol. 1994; 45: 587-90.
143. Strowski MZ, Dashkevicz MP, Parmar RM, et al Somatostatin receptor subtypes 2 and 5 inhibit corticotropin-releasing hormone-stimulated adrenocorticotropin secretion from AtT-20 cells. Neuroendocrinology. 2002; 75: 339-46.
144. Cervia D, Fehlmann D, Hoyer D. Native somatostatin sst2 and sst5 receptors functionally coupled to G(i/o)-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367: 578-87.
145. Cervia D, Langenegger D, Schuepbach E, et al Binding and functional properties of the novel somatostatin analogue KE 108 at native mouse somatostatin receptors. Neuropharmacology. 2005; 48: 881-93.
146. Birnbaumer L, Abramowitz J, Yatani A, et al Roles of G proteins in coupling of receptors to ionic channels and other effector systems. Crit Rev Biochem Mol Biol. 1990; 25: 225-44.
147. Yatani A, Birnbaumer L, Brown AM. Direct coupling of the somatostatin receptor to potassium channels by a G protein. Metabolism. 1990; 39; 91-5.
148. Kreienkamp HJ, Honck HH, Richter D. Coupling of rat somatostatin receptor subtypes to a Gprotein gated inwardly rectifying potassium channel (GIRK1). FEBS Lett. 1997; 419: 92-4.
149. + currents in GH3 cells through activation of multiple somatostatin receptors. Endocrinology. 2005; 146: 4975-84.
150. Chen L, Fitzpatrick VD, Vandlen RL, et al Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells. J Biol Chem. 1997; 272: 18666-72.
151. Fujii Y, Gonoi T, Yamada Y, et al Somatostatin receptor subtype SSTR2 mediates the inhibition of highvoltage-activated calcium channels by somatostatin and its analogue SMS 201-995. FEBS Lett. 1994; 355: 117-20.
152. 2+ current in the pituitary cell line AtT-20. Neuroscience. 1996; 71: 1073-81.
153. Moeller I, Bunn SJ, Marley PD. Actions of somatostatin on perfused bovine adrenal glands and cultured bovine adrenal medullary cells. Brain Res. 1989; 484: 192-202.
154. 2+ mobilization. Biochem Biophys Res Commun. 1994; 200: 986-92.
155. Kubota A, Yamada Y, Kagimoto S, et al Multiple effector coupling of somatostatin receptor subtype SSTR1. Biochem Biophys Res Commun. 1994; 204: 176-86.
156. Hipkin RW, Wang Y, Schonbrunn A. Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor. J Biol Chem. 2000; 275: 5591-9.
157. Akbar M, Okajima F, Tomura H, et al Phospholipase C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells. FEBS Lett. 1994; 348: 192-6.
158. Hirabayashi T, Murayama T, Shimizu T. Regulatory mechanism and physiological role of cytosolic phospholipase A2. Biol Pharm Bull. 2004; 27: 1168-73.
159. Sun GY, Xu J, Jensen MD, et al Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. J Lipid Res. 2004; 45: 205-13.
160. Judd AM, Koike K, MacLeod RM. GRF increases release of growth hormone and arachidonate from anterior pituitary cells. Am J Physiol. 1985; 248: E438-42.
161. Duerson K, White RE, Jiang F, et al Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid. Neuropharmacology. 1996; 35: 949-61.
162. Sellers LA, Feniuk W, Humphrey PP, et al Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation. J Biol Chem. 1999; 274: 16423-30.
163. Komatsuzaki K, Terashita K, Kinane TB, et al Somatostatin type V receptor activates c-Jun N terminal kinases via G alpha(12) family G proteins. Biochem Biophys Res Commun. 2001; 289: 1211-7.
164. Thermos K. Novel signals mediating the functions of somatostatin: the emerging role of NO/cGMP. Mol Cell Endocrinol. 2008; 286: 49-57.
165. Lopez F, Ferjoux G, Cordelier P, et al Neuronal nitric oxide synthase: a substrate for SHP-1 involved in sst2 somatostatin receptor growth inhibitory signaling. FASEB J. 2001; 15: 2300-2.
166. Cordelier P, Estève JP, Bousquet C, et al Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci USA. 1997; 94: 9343-8.
167. McDonald LJ, Murad F. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med. 1996; 211: 1-6.
168. Corbin JD, Francis SH. Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem. 1999; 274: 13729-32.
169. Cordelier P, Estève JP, Najib S, et al Regulation of neuronal nitric-oxide synthase activity by somatostatin analogs following SST5 somatostatin receptor activation. J Biol Chem. 2006; 281: 19156-71.
170. Florio T, Morini M, Villa V, et al Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003; 144: 1574-84.
171. Hou C, Gilbert RL, Barber DL. Subtype specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2. J Biol Chem. 1994; 269: 10357-62.
172. Grozinsky-Glasberg S, Franchi G, Teng M, et al Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line. Neuroendocrinology. 2008; 87: 168-81.